[RESULTS] In addition , the results for the all therapeutic effects showed identical trends to the results obtained in the original analysis , including the statistically similar effects of ETV and ETV maleate treatment-induced decreases in mean HBV DNA level at weeks 12 , 24 , and 48 ( ETV : by 4.28 , 5.00 , and 5.53 log10 IU/ml vs. ETV maleate : by 4.46 , 4.99 , and 5.51 log10 IU/ml , respectively ; all vs. baseline P more than 0.05 ) , achievement of undetectable levels of serum HBV DNA ( less than 20 IU/ml ) at week 48 ( ETV : 38.18 % vs. ETV maleate : 35.19 % ; P more than 0.05 ) , HBeAg loss rates at week 48 ( ETV : 10.91 % vs. ETV maleate : 12.96 % ; P more than 0.05 ) , HBeAg seroconversion rates at week 48 ( ETV : 7.77 % vs. ETV maleate : 10.38 % ; P more than 0.05 ) , normalization of alanine aminotransferase at week 48 ( ETV : 75.47 % vs. ETV maleate : 82.86 % ; P more than 0.05 ) , and overall incidence of AE ( ETV : 18.02 % vs. ETV maleate : 17.43 % ; P more than 0.05 ) .